Next Steps for KRAS Inhibitors Focus on Tackling Resistance
The recent approval of sotorasib for the treatment of patients with advanced KRAS G12C‑mutant non‑small cell lung cancer (NSCLC) marks a milestone for cancer therapy.
The recent approval of sotorasib for the treatment of patients with advanced KRAS G12C‑mutant non‑small cell lung cancer (NSCLC) marks a milestone for cancer therapy.
Sotorasib is the first FDA‑approved KRAS G12C inhibitor, representing a landmark advancement in targeted therapy for a historically undruggable oncogene in multiple solid tumors, notably NSCLC.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT